PT  - JOURNAL ARTICLE
AU  - Norori, Natalia
AU  - de Biase, Chiara
AU  - Wong, Yui Hang
AU  - Crabtree, Sadie Robson
AU  - Cox, Matt
AU  - Appleby, Esther
AU  - Seggie, Andrew
AU  - Brown, Rachel
AU  - Rylance, Amy
TI  - Evaluating whether Prostate Cancer UK’s risk checker is a help or hindrance to prostate-specific antigen testing policy: a mixed-methods study
AID  - 10.3399/BJGPO.2024.0040
DP  - 2024 Jul 01
TA  - BJGP Open
PG  - BJGPO.2024.0040
VI  - 8
IP  - 2
4099  - http://bjgpopen.org/content/8/2/BJGPO.2024.0040.short
4100  - http://bjgpopen.org/content/8/2/BJGPO.2024.0040.full
SO  - BJGP Open2024 Jul 01; 8
AB  - Background The UK has an informed choice testing policy for prostate cancer. The prostate-specific antigen (PSA) blood test is available for free to any man aged ≥50 years who requests it and has been informed of the harms and benefits. This policy leads to differences in PSA testing rates, which can exacerbate health inequalities.Aim To assess whether Prostate Cancer UK’s risk checker helps men at risk of prostate cancer make an informed choice about the PSA test.Design & setting Mixed-methods study in the UK.Method In total, 1181 men at risk, their partners, and clinical experts participated in surveys, focus groups, and one-to-one interviews. Data on risk checker completions by sociodemographic factors were analysed over time. Data from general practices that sent the risk checker to their patients were collected and analysed for service monitoring purposes.Results There was a strong assumption that testing must be good, and therefore a need to emphasise the pros and cons of the test and that having it was the patient’s decision. Men believed their GP would invite them for PSA testing. On the impact of the risk checker, 79.6% of men who completed it had at least one prostate cancer risk factor; the average time they interacted with the information in the tool was 9 minutes 28 seconds; and 75.7% felt the tool had equipped them to make an informed choice.Conclusion Online decision-making tools, such as the risk checker, can help reach men at high risk of prostate cancer and support them in making an informed choice about the PSA test.